Geninus is showing strong performance. It appears to have attracted attention due to its outstanding technological capabilities in diabetes, artificial intelligence (AI), and cancer diagnosis, areas that global pharmaceutical companies have recently shown interest in.
As of 10:28 AM on the 28th, Geninus was trading at 4,480 KRW, up 12.42% (495 KRW) compared to the previous trading day.
Hana Kang, a researcher at Ebest Investment & Securities, explained, "The global bio market is focusing on diabetes and obesity treatments due to the recent launches and shortages of diabetes and obesity drugs by global big pharma."
She added, "Geninus has entered the diabetes market beyond cancer diagnosis through collaboration with Kakao Healthcare," and "is currently promoting a precision medical AI service business related to diabetes." Furthermore, she noted, "Kakao Healthcare is cooperating with i-SENS, the number one continuous glucose monitoring company in Korea," adding, "synergy effects are expected."
She analyzed, "We expect clinical entry of an anti-cancer vaccine derived from the AI new drug development platform and an increase in sales," and "it is no exaggeration to say that Geninus is a global top-tier company in the single-cell field." She also emphasized, "In February this year, they published a paper on single-cell analysis results of immune cells and drug responses to immuno-oncology drugs in the Journal of ImmunoTherapy of Cancer, strengthening their position in the single-cell field."
Researcher Kang explained, "As a leader in the single-cell field, they are building an AI new drug development platform based on single-cell technology," and "they demonstrated superiority over global anti-cancer vaccine development companies by revealing preclinical data of a customized anti-cancer vaccine derived from the tumor neoantigen prediction platform ‘Baeksinus’ at EACR2023."
She expressed expectations, saying, "The synergy between precision diagnostics based on single-cell and the AI new drug development platform could enable a jump-up depending on the increase of overseas partners or overseas sales," and "as one of the domestic biotech companies with the largest amount of cancer patient data, the possibility of additional contracts or sales growth in the ‘cancer’ field is valid."
Park Woong-yang, CEO of Geninus, recently stated in an interview with the media, "Single-cell analysis is the so-called 'ultimate technology,'" explaining, "You need to understand human cells to know how drugs respond." He continued, "It is a technology that makes this possible," emphasizing, "It can map cancer cells existing in the human body and analyze how our body fights cancer cells and how drugs respond."
CEO Park said, "Single-cell analysis is essential to cure cancer," and "the essence of single-cell analysis is to analyze each component of cancer tissue to find cancer treatments."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
